Merck is increasing its investment in India and introducing products and solutions to support biosimilar manufacturing in the country, Udit Batra, executive board member of the 350-year-old German pharmaceutical and chemical maker said on Thursday.
“We expect strong growth from India. We are ready to bring bioproduction technology in India in a meaningful way. We have already done that successfully in other countries,” said Delhi-born Batra who heads the company's life science division.
While Merck plans to introduce new anti-cancer drugs in India, the main growth driver for its business in India will come from sale of products and services